Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biodyn Regulatory News (OBD)

Share Price Information for Oxford Biodyn (OBD)

Share Price is delayed by 15 minutes
Get Live Data
0.10    -0.01 (-9.09%)
Bid:
0.09
Ask:
0.11
Spread: 0.02 (22.222%)
Market Cap: £4.29m
OBD Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biodyn Share Chart

Holding(s) in Company

6 Feb 2025 07:00

RNS Number : 0918W
Oxford BioDynamics PLC
06 February 2025
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

OXFORD BIODYNAMICS PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify) iii:

 

3. Details of person subject to the notification obligation iv

Name

Arbuthnot Latham (Nominees) Limited

City and country of registered office (if applicable)

London, United Kingdom

4. Full name of shareholder(s) (if different from 3.) v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

05/02/2025

6. Date on which issuer notified (DD/MM/YYYY):

05/02/2025

 

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

3.79%

3.79%

74,250,303

Position of previous notification (if applicable)

9.13%

9.13%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type of shares ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct (DTR5.1)

Indirect (DTR5.2.1)

Direct (DTR5.1)

Indirect (DTR5.2.1)

GB00BD5H8572

74,250,303

3.79%

SUBTOTAL 8. A

74,250,303

3.79%

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expiration date x

Exercise/ Conversion Period xi

Number of voting rights that may be acquired if the instrument isexercised / converted.

% of voting rights

SUBTOTAL 8. B 1

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expiration date x

Exercise/ Conversion Pe-riod xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

X

Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

 

11. Additional information xvi

· Based on total voting rights of 1,957,577,641.

· Oxford Biodynamics has recently successfully raised gross proceeds of £7 million in accordance to a placing, and therefore an additional 1,400,000,000 new Ordinary Shares will be issued to the Placing and Subscriptions at the Issue Price. "therefore an additional 1,400,000,000 new Ordi-nary Shares will be issued to the Placing and Subscriptions at the Issue Price".

· As this placing of shares has now settled, the report is being filed.

 

Place of completion

London

Date of completion

05/02/2025

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEAFASEDXSEAA
Date   Source Headline
30th Jun 20267:02 amRNS-RUS contract sales partnership
30th Jun 20267:01 amRNSInterim Results
30th Jun 20267:00 amRNSAppointment of Chief Executive Officer
15th Apr 20267:00 amRNSBoard Appointment
30th Mar 20264:07 pmRNSHolding(s) in Company
20th Mar 202612:03 pmRNSHolding(s) in Company
3rd Mar 20269:30 amRNS-ROBD to present at PMWC 2026
17th Feb 20267:00 amRNSChange of Nominated Adviser
27th Jan 202612:52 pmRNSHolding(s) in Company
26th Jan 202612:10 pmRNSResult of AGM
26th Jan 20267:00 amRNSBoard Change
22nd Dec 202511:00 amRNSPublication of 2025 Annual Report
22nd Dec 202511:00 amRNSPublication of 2025 Annual Report
16th Dec 20257:00 amRNSPreliminary Results and Notice of AGM
9th Dec 202512:40 pmRNSNotice of Results
3rd Dec 20257:00 amRNSStatement re share price, update on EpiSwitch PSE
25th Nov 20252:05 pmRNSHolding(s) in Company
12th Nov 20257:00 amRNSHolding(s) in Company
11th Nov 20252:12 pmRNSHolding(s) in Company
11th Nov 20252:11 pmRNSHolding(s) in Company
11th Nov 20252:10 pmRNSHolding(s) in Company
10th Nov 20257:00 amRNSPDMR Dealing / Grant of Share Options
7th Nov 202511:32 amRNSResult of General Meeting/PDMR Dealings
22nd Oct 20257:00 amRNSFundraising, Posting of Circular & Notice of GM
14th Oct 20257:00 amRNS-ROBD in New Report on NHS Prostate Cancer Screening
8th Oct 20257:00 amRNSOBD and UEA develop test for Chronic Fatigue
10th Sep 20257:00 amRNSHolding(s) in Company
4th Sep 202510:00 amRNS-RStudy confirms clinical utility of EpiSwitch CiRT
13th Aug 20257:00 amRNSCollaboration with Google Cloud
18th Jul 20253:11 pmRNSHolding(s) in Company
17th Jul 20257:01 amRNS-RGenomeWeb to host joint Agilent/OBD presentation
17th Jul 20257:00 amRNSHolding(s) in Company
15th Jul 20255:20 pmRNSHolding(s) in Company
15th Jul 20257:00 amRNS-RPfizer study on EpiSwitch biomarkers
1st Jul 20253:00 pmRNSHolding(s) in Company
30th Jun 20257:00 amRNSInterim Results
27th Jun 20251:30 pmRNSHolding(s) in Company
9th May 20257:00 amRNS-ROBD’s Oxford Lab accredited by UKAS
10th Apr 20254:10 pmRNSDirector/PDMR Shareholding
2nd Apr 20257:00 amRNSPDMR Dealing
28th Mar 202510:35 amRNSResult of AGM
17th Mar 20257:00 amRNSBoard Changes
14th Mar 20255:25 pmRNSHolding(s) in Company
13th Mar 20257:00 amRNS-RExpansion of OBD/Bupa UK insurance partnership
5th Mar 20254:00 pmRNSPublication of 2024 Annual Report
3rd Mar 20257:00 amRNSPDMR Dealing / Grant of Share Options
28th Feb 20257:00 amRNSPreliminary Results and Notice of AGM
21st Feb 202510:00 amRNSNotice of Preliminary Results
17th Feb 20251:07 pmRNSHolding(s) in Company
12th Feb 20254:48 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.